Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
Despite already having three products on the market, unlike many of its Hong Kong-listed peers, the drug maker is struggling to cover its daily operational costs Key Takeaways: Mabwell said…
Health Guard plans dual listing to fund HPV vaccine fight
After a Beijing IPO last year, the loss-making biotech has also filed for a Hong Kong listing to better compete in the crowded market for HPV vaccines Key Takeaways: Beijing…
